

## ADHERIUM EXPANDS ITS INTERNATIONAL PRESENCE ANNOUNCES MR THOMAS LYNCH AS CHAIRMAN AND DR DOUG WILSON AS MEDICAL DIRECTOR

1 September 2016: Adherium Limited (ASX:ADR), *a global leader in digital health technologies that address sub-optimal medication use in chronic disease*, today announced Mr Thomas Lynch as Adherium's new Chairman, and Dr Doug Wilson as Adherium's executive Medical Director.

Mr Lynch's appointment follows a global search for a high profile Director with broad international experience in the healthcare sector in North America and Europe.

Mr Lynch has extensive experience of biotechnology and specialty pharma. He has just stepped down as Chair of Icon plc, one of the world's largest clinical research organisations having served on its board for 22 years. He is also chair of Evofem Biosciences Inc and Profectus Biosciences Inc, two privately-held US biotechnology companies. Mr Lynch serves as a non-executive director of GW Pharma plc, a biotechnology company listed on NASDAQ and AIM. In a pro-bono capacity, Mr Lynch serves as chair of the Ireland East Hospital Group, the largest hospital group in Ireland. Mr Lynch has also served in a range of roles at Elan Corporation plc and Amarin Corporation plc. Throughout his career, Mr Lynch has been involved in the listing of a number of companies on the NASDAQ market and brings significant international capital markets experience to Adherium.

Dr Wilson is stepping down from the board, moving to a part-time executive role as Adherium's Medical Director, where he will work closely with the management team to assist in steering the Company's clinical development and strategic path for the next phase of growth. He described his departure at the anniversary of the IPO and the first year as a public company, as timely, as the year has seen the Company grow to 50 personnel, and a significantly expanded breadth of market opportunities. New senior staff are adding strong international experience to the Company.

Recently established business hubs in the US and UK are accelerating Adherium's access to new business. The Adherium technology platform is advancing rapidly with new devices incorporating more sensors to broaden the application beyond drug detection to inhaler technique and other data. The first Adherium device that uses Adherium's technology beyond-the-inhaler has been developed, and a new suite of web services have been released. This is a logical time for Dr Wilson to move from the Board to free the Chair role for the new major international candidate.

Adherium's Group CEO, Garth Sutherland said, "On behalf of the Adherium Board, we offer our sincere thanks to Dr Wilson for the major contribution he has made to Adherium's growth over the last four years, and we warmly welcome Mr Thomas Lynch to the Adherium Board for our next major phase of growth."

**\*\*ENDS\*\***

## ABOUT ADHERIUM

Adherium (ASX:ADR) is an Australian Securities Exchange listed company which develops, manufactures and supplies digital health technologies which address sub-optimal medication use and improve health outcomes in chronic disease.

Adherium operates globally from bases in the USA, Europe and Australasia.

Adherium is a provider of digital health solutions to patients, pharmaceutical companies, healthcare providers and contract research organizations. The Company's proprietary Smartinhaler™ platform has been independently proven to improve medication adherence and health outcomes for patients with chronic respiratory disease. Adherium has the broadest range of "smart" medication sensors for respiratory medications globally.

The Smartinhaler™ platform has so far been used in more than 65 projects (clinical, device validation or other) and has been referenced in 56 peer reviewed journal articles. Clinical outcomes data has proven that the Smartinhaler™ platform can improve adherence by up to 59% in adults and 180% in children and reduce severe episodes by 60% in adults, leading to improved quality-of-life and demonstrating a substantial gain over current best practice treatment. The Company has received FDA 510(k) notifications for clearance to market and CE Marks for its devices and software, which allows it to sell these devices into international markets.

[www.adherium.com](http://www.adherium.com)    [www.smartinhaler.com](http://www.smartinhaler.com)

### Enquiries:

At Adherium:		
<b>Corporate</b> Julia Chambers Head of Corporate Development M: +64 27 807 8153 E: <a href="mailto:juliac@adherium.com">juliac@adherium.com</a>	<b>North America</b> James Hattersley Senior Vice President, Business Development, North America M: +1 610 955 5886 E: <a href="mailto:jamesh@adherium.com">jamesh@adherium.com</a>	
Media enquiries:		
<b>Australia and New Zealand</b> Rudi Michelson Monsoon Communications D: +61 3 9620 3333 E: <a href="mailto:rudim@monsoon.com.au">rudim@monsoon.com.au</a>	<b>North America</b> Erich Sandoval Lazar Partners D: +1 213-908-6226 E: <a href="mailto:esandoval@lazarpartners.com">esandoval@lazarpartners.com</a>	<b>Europe</b> Sue Charles/Rozi Morris Instinctif Partners D: +44 (0)20 7866 7860 E: <a href="mailto:adherium@instinctif.com">adherium@instinctif.com</a>